Evaluation of Physicochemical Properties, Pharmacokinetics, Biodistribution, Toxicity, and Contrast-Enhanced Cancer MRI of a Cancer-Targeting Contrast Agent, MT218-Reference-Cited by-同舟云学术

Evaluation of Physicochemical Properties, Pharmacokinetics, Biodistribution, Toxicity, and Contrast-Enhanced Cancer MRI of a Cancer-Targeting Contrast Agent, MT218

Published:2022-05-05 Issue:10 Volume:57 Page:639-654
ISSN:1536-0210
Container-title:Investigative Radiology
language:en
Short-container-title:Invest Radiol

Author:

Li Yajuan,Gao Songqi,Jiang Hongfa,Ayat Nadia,Laney Victoria,Nicolescu Calin,Sun Wenyu,Tweedle Michael F.,Lu Zheng-Rong

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Radiology, Nuclear Medicine and imaging,General Medicine

Reference60 articles.

1. Brain tumor enhancement in magnetic resonance imaging: comparison of signal-to-noise ratio (SNR) and contrast-to-noise ratio (CNR) at 1.5 versus 3 tesla;Invest Radiol,2005

2. Predicting control of primary tumor and survival by DCE MRI during early therapy in cervical cancer;Invest Radiol,2009

3. Prebiopsy multiparametric MRI and PI-RADS version 2.0 for differentiating histologically benign prostate disease from prostate cancer in biopsies: a retrospective single-center comparison;Clin Imaging,2021

4. SelectMDx and multiparametric magnetic resonance imaging of the prostate for men undergoing primary prostate biopsy: a prospective assessment in a multi-institutional study;Cancers (Basel),2021

5. Magnetic resonance imaging using gadolinium labeled monoclonal antibody;Invest Radiol,1985

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Magnetic Resonance Imaging of Fibroblast Activation Protein Using a Targeted Gadolinium-Based Contrast Agent;Molecular Pharmaceutics;2024-08-19

2. MR Molecular Imaging of Extradomain-B Fibronectin for Assessing Progression and Therapy Resistance of Prostate Cancer;Chemical & Biomedical Imaging;2024-06-11

3. Assessment of the Efficacy of the Combination of RNAi of lncRNA DANCR with Chemotherapy to Treat Triple Negative Breast Cancer Using Magnetic Resonance Molecular Imaging;Bioconjugate Chemistry;2024-03-06

4. Protein MRI Contrast Agents as an Effective Approach for Precision Molecular Imaging;Investigative Radiology;2024-02

5. Pharmacokinetics and Tolerability of the Cancer-Targeting MRI Contrast Agent MT218 in Healthy Males;Investigative Radiology;2023-12-08